''Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat

multiple sclerosis Multiple (cerebral) sclerosis (MS), also known as encephalomyelitis disseminata or disseminated sclerosis, is the most common demyelinating disease, in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This d ...

. The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site. Peginterferon beta-1a was approved for medical use in the United States and in the European Union in 2014. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

Medical uses

In the United States peginterferon beta-1a is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. In the European Union peginterferon beta-1a is indicated for the treatment of relapsing remitting multiple sclerosis in adults.

References

External links

* * Antineoplastic and immunomodulating drugs Multiple sclerosis {{antineoplastic-drug-stub